Amredobresib

Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC50 values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer.


Cat. No.: EX-A11904	Purity: >98%

	Chemical structure of Amredobresib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	588	In-stock
100mg	888	In-stock
250mg	1558	In-stock
500mg	2088	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	BI894999
CAS No.	1610044-98-8
Purity	>98%
Formula	C26H29N9
Mol Weight	467.5688
Color	Light yellow to yellow
State	Solid
Solubility	DMSO : 0.5 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder 4°C, sealed storage, away from moisture and light; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Ulrike Tontsch-Grunt, et al. Combination treatment of acute myeloid leukemia. Patent WO2019145410A1. [2]. Shaonan Wang, et al. Method for administration of an anti cancer agent. Patent WO2021175824A1. [3]. Tontsch-Grunt U, et al. Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. Br J Cancer. 2022 Aug;127(3):577-586. [4]. Tontsch-Grunt U, et al. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018 May 1;421:112-120. [5]. Gerlach D, et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene. 2018 May;37(20):2687-2701.
CoA	CoA of Amredobresib

Smiles:	CC1=NN=C2N1C=C(N=C2NC)C3=NC4=C(N3CC5=CC=CC=C5)C=C(C=C4)N6CCN(CC6)C


		Search